Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Redox Biol ; 37: 101735, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-33011677

RESUMO

The activity of Thioredoxin-1 (Trx-1) is adjusted by the balance of its monomeric, active and its dimeric, inactive state. The regulation of this balance is not completely understood. We have previously shown that the cytoplasmic domain of the transmembrane protein A Disintegrin And Metalloprotease 17 (ADAM17cyto) binds to Thioredoxin-1 (Trx-1) and the destabilization of this interaction favors the dimeric state of Trx-1. Here, we investigate whether ADAM17 plays a role in the conformation and activation of Trx-1. We found that disrupting the interacting interface with Trx-1 by a site-directed mutagenesis in ADAM17 (ADAM17cytoF730A) caused a decrease of Trx-1 reductive capacity and activity. Moreover, we observed that ADAM17 overexpressing cells favor the monomeric state of Trx-1 while knockdown cells do not. As a result, there is a decrease of cell oxidant levels and ADAM17 sheddase activity and an increase in the reduced cysteine-containing peptides in intracellular proteins in ADAM17cyto overexpressing cells. A mechanistic explanation that ADAM17cyto favors the monomeric, active state of Trx-1 is the formation of a disulfide bond between Cys824 at the C-terminal of ADAM17cyto with the Cys73 of Trx-1, which is involved in the dimerization site of Trx-1. In summary, we propose that ADAM17 is able to modulate Trx-1 conformation affecting its activity and intracellular redox state, bringing up a novel possibility for positive regulation of thiol isomerase activity in the cell by mammalian metalloproteinases.


Assuntos
Proteína ADAM17 , Cisteína , Tiorredoxinas , Cisteína/metabolismo , Células HEK293 , Humanos , Conformação Molecular , Oxirredução , Compostos de Sulfidrila , Tiorredoxinas/genética , Tiorredoxinas/metabolismo
3.
Mol Neuropsychiatry ; 3(1): 37-52, 2017 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-28879200

RESUMO

Schizophrenia (SCZ) is a serious neuropsychiatric disorder that manifests through several symptoms from early adulthood. Numerous studies over the last decades have led to significant advances in increasing our understanding of the factors involved in SCZ. For example, mass spectrometry-based proteomic analysis has provided important insights by uncovering protein dysfunctions inherent to SCZ. Here, we present a comprehensive analysis of the nuclear proteome of postmortem brain tissues from corpus callosum (CC) and anterior temporal lobe (ATL). We show an overview of the role of deregulated nuclear proteins in these two main regions of the brain: the first, mostly composed of glial cells and axons of neurons, and the second, represented mainly by neuronal cell bodies. These samples were collected from SCZ patients in an attempt to characterize the role of the nucleus in the disease process. With the ATL nucleus enrichment, we found 224 proteins present at different levels, and 76 of these were nuclear proteins. In the CC analysis, we identified 119 present at different levels, and 24 of these were nuclear proteins. The differentially expressed nuclear proteins of ATL are mainly associated with the spliceosome, whereas those of the CC region are associated with calcium/calmodulin signaling.

4.
Proteomics Clin Appl ; 10(12): 1148-1158, 2016 12.
Artigo em Inglês | MEDLINE | ID: mdl-27439988

RESUMO

Psychiatric disorders are one of the biggest burdens to society, with significant personal and economical costs. Schizophrenia (SCZ), among them, is still poorly understood, and its molecular characterization is crucial to improve patients' diagnosis and treatment. The combination of genetic, biochemical, and environmental factors leads to systemic alterations, which are yet to be fully comprehended. Thus, understanding those missing links by connecting some molecular reports of SCZ is essential. From postmortem brain to animal models and cell culture, new tools are emerging, including recent advances in proteomics, and there is a need to apply them to solve these problems. Here, we review some of those features, mainly related to where proteomics could help, and discuss whether those new technologies could and should be applied to psychiatric disorder studies.


Assuntos
Proteômica/métodos , Esquizofrenia/metabolismo , Animais , Exossomos/metabolismo , Edição de Genes , Humanos , Esquizofrenia/genética , Esquizofrenia/patologia , Células-Tronco/metabolismo
5.
Carbohydr Polym ; 136: 177-86, 2016 Jan 20.
Artigo em Inglês | MEDLINE | ID: mdl-26572344

RESUMO

Disorders of hemostasis can produce innumerous problems. Polysaccharides have been studied both as anticoagulant and as procoagulant agents. A mannan with a main chain of α-(1 → 6)-linked-Manp units, branched at O-2 mainly by side-chains of 2-O-linked-α-Manp units was chemically sulfated, structurally characterized by NMR and GC-MS (methylation, desulfation and methylation with trideuterated iodomethane), and tested in vitro and in vivo on blood coagulation models. Chemical analyses indicate a high degree of substitution on the sulfated polysaccharide. This polymer acted as a procoagulant agent, increasing blood coagulation in normal and hemophilic plasma, activated platelet aggregation and also decreased ex vivo aPTT. Polymers such as the sulfated mannan could be a helpful source of hemostatic agents to prevent hemorrhagic states.


Assuntos
Coagulação Sanguínea/efeitos dos fármacos , Mananas/química , Mananas/farmacologia , Sulfatos/química , Animais , Fator XII/metabolismo , Fator Xa/metabolismo , Feminino , Hemofilia A/fisiopatologia , Humanos , Hidrocarbonetos Iodados/química , Metilação , Agregação Plaquetária/efeitos dos fármacos , Ratos , Ratos Wistar , Trombina/metabolismo , Trombose Venosa/fisiopatologia
6.
Proteomics Clin Appl ; 10(4): 442-55, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26679983

RESUMO

Schizophrenia is an incurable neuropsychiatric disorder managed mostly by treatment of the patients with antipsychotics. However, the efficacy of these drugs has remained only low to moderate despite intensive research efforts since the early 1950s when chlorpromazine, the first antipsychotic, was synthesized. In addition, antipsychotic treatment can produce often undesired severe side effects in the patients and addressing these remains a large unmet clinical need. One of the reasons for the low effectiveness of these drugs is the limited knowledge about the molecular mechanisms of schizophrenia, which impairs the development of new and more effective treatments. Recently, proteomic studies of clinical and preclinical samples have identified changes in the levels of specific proteins in response to antipsychotic treatment, which have converged on molecular pathways such as cell communication and signaling, inflammation and cellular growth, and maintenance. The findings of these studies are summarized and discussed in this review and we suggest that this provides validation of proteomics as a useful tool for mining drug mechanisms of action and potentially for pinpointing novel molecular targets that may enable development of more effective medications.


Assuntos
Antipsicóticos/efeitos adversos , Proteínas Mitocondriais/metabolismo , Proteínas do Tecido Nervoso/metabolismo , Proteoma/metabolismo , Proteômica/métodos , Esquizofrenia/tratamento farmacológico , Animais , Antipsicóticos/administração & dosagem , Aripiprazol/administração & dosagem , Aripiprazol/efeitos adversos , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Encéfalo/patologia , Clorpromazina/administração & dosagem , Clorpromazina/efeitos adversos , Clozapina/administração & dosagem , Clozapina/efeitos adversos , Modelos Animais de Doenças , Regulação da Expressão Gênica , Glicólise/efeitos dos fármacos , Humanos , Proteínas Mitocondriais/genética , Proteínas do Tecido Nervoso/genética , Fosforilação Oxidativa/efeitos dos fármacos , Proteoma/genética , Esquizofrenia/genética , Esquizofrenia/metabolismo , Esquizofrenia/patologia , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...